双靶点药物NL-101的抗多发性骨髓瘤活性及其机制研究
Antitumor effects and the mechanisms of dual-targeting drug NL-101 on human multiple myeloma
-
摘要: 研究具有组蛋白去乙酰化酶(histone deacetylase，HDAC)抑制和DNA损伤双靶点化合物NL-101的体内外抗多发性骨髓瘤活性及其机制研究。在10株多发性骨髓瘤细胞株中，采用CTG法检测化合物NL-101对肿瘤细胞增殖的影响以及在RPMI 8226细胞中NL-101与硼替佐米的联用效果，采用流式细胞仪检测NL-101对细胞周期的影响，Western blot检测NL-101对乙酰化组蛋白H3、乙酰化α-Tubulin和磷酸化Histone H2A.X的表达影响，并在RPMI 8226多发性骨髓瘤细胞皮下移植瘤模型中考察NL-101单用以及与硼替佐米联用的抑瘤效果。研究结果表明，NL-101能同时产生HDAC抑制剂和DNA烷化剂双重活性，不但抑制肿瘤细胞组蛋白去乙酰化水平，而且增加DNA损伤，最终诱导细胞周期阻滞和细胞凋亡。在细胞水平和动物移植瘤模型中均表现出较强的抗肿瘤活性，优于阳性对照药美法仑，而且与硼替佐米联用具有协同增效作用。NL-101有望成为一个全新的抗多发性骨髓瘤药物。Abstract: The antitumor activities of NL-101, aHDACi/DNA damage dual-targeting drug, on human multiple myeloma in vitro and in vivo were studied. Furthermore, the primary mechanisms were revealed. We detected the anti-proliferative activity of NL-101 on 10 human multiple myeloma cell lines, and the combinational effect of NL-101 and bortezomib on RPMI 8226 cell line. The inducing effects of NL-101 on cell cycle arrest and apoptosis were detected by FACS. The effects of NL-101 on acetyled-Histone H3, total Histone H3, acetyled α-Tubulin, total α-Tubulin, phospho-Histone H2A. X and total Histone H2A. X were evaluated by Western blott. We also demonstrated the antitumor activity of NL-101 and the combinational effect of NL-101 and bortezomib on RPMI 8226 xenograft tumor model in vivo. Results showed that NL-101 possessed strong antitumor activities on human multiple myeloma cells in vitro and in vivo. NL-101exhibited significant HDAC inhibitory activity and DNA alkylating activity. NL-101not only inhibited histone deacetylation level, but also increased the DNA damage in multiple myeloma cells. Meanwhile, NL-101 induced cell cycle arrest and apoptosis. Also, the synergistic effect of NL-101 was discovered when combined with bortezomib in vitro and in vivo. These data demonstrated that NL-101 may be a potent agent for the treatment of human multiple myeloma in future.
-
Keywords:
- NL-101 /
- DNA damage /
- HDAC inhibitor(HDACi) /
- dual-targeting /
- antitumor activity
-
-
[1] Manal M,Chandrasekar MJ,Gomathi Priya J.Inhibitors of histone deacetylase as antitumor agents:a critical review[J].Bioorg Chem,2016,67:18-42. [2] Groselj B, Sharma NL, Hamdy FC, et al. Histonedeacetylase inhibitors as radiosensitisers:effects on DNA damage signalling and repair[J]. Bri J Cancer,201,108(4):748-754. [3] Sanchez E, Shen J, Steinberg J, et al. The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo[J].Leuk Res,2011,35:373-379. [4] Lee CK,Wang S,Huang X,et al.HDAC inhibition synergistically enhances alkylator-induced DNA damage responses and apoptosis in multiple myeloma cells[J].Cancer Lett,2010,296:233-240. [5] Ai T,Cui H,Chen L.Multi-targeted histone deacetylase inhibitors in cancer therapy[J].Curr Med Chem,2012,19:475-487. [6] Cai B,Lyu H,Huang J,et al.Combination of bendamustine and entinostat synergistically inhibits proliferation of multiple myeloma cells via induction of apoptosis and DNA damage response[J].Cancer Lett,2013,335:343-350. [7] Mehrling T,Chen Y.The alkylating-HDAC inhibition fusion principle:taking chemotherapy tothe next level with the first in class molecule EDO-S101[J].Anticancer Agents Med Chem,2016,16(1):20-28. [8] Yu J,Qiu S,Ge Q,et al.A novel SAHA-bendamustinehybridinduces apoptosis of leukemia cells[J].Oncotarget,2015,6(24):20121-20131. [9] Gentile M,Vigna E,Recchia AG,et al.Bendamustine in multiple myeloma[J].Eur J Haematol,2015,95(5):377-388. [10] Dimopoulos M,Siegel DS,Lonial S,et al.Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma(VANTAGE 088):a multicentre,randomised,double-blind study[J].Lancet Oncol,2013,14(11):1129-1140. [11] Yalon M,Tuval-Kochen L.Overcoming resistance of cancer cells to PARP-1 Inhibitors with three different drug combinations[J].PLoS ONE,2016,11(5):e0155711.
计量
- 文章访问数: 838
- HTML全文浏览量: 1
- PDF下载量: 2164
下载:
